← Back to Search

Virus Therapy

Neural Stem Cell Virotherapy for Brain Cancer

Phase 1
Recruiting
Led By Jana L Portnow
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 2 weeks from taking the last dose of a targeted agent
The patient must be in need of surgery for tumor resection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing a new cancer treatment consisting of neural stem cells that carry a virus. The hope is that this will kill more tumor cells than the current standard of care.

Who is the study for?
This trial is for adults with high-grade gliomas that have returned after treatment. Candidates must have adequate blood counts, organ function, and be at least 6 weeks past certain chemotherapies. They need surgery for tumor resection, not be pregnant or breastfeeding, use contraception if applicable, and cannot have specific HLA antibodies or active CNS infections.Check my eligibility
What is being tested?
The trial tests multiple doses of NSC-CRAd-S-pk7 on patients with recurrent high-grade gliomas. This therapy uses neural stem cells carrying a virus to target and kill cancer cells during the patient's surgery for tumor resection.See study design
What are the potential side effects?
Potential side effects may include reactions related to the immune system due to viral components in the treatment, typical risks associated with surgical procedures like infection or bleeding, as well as any unforeseen complications from introducing modified stem cells into the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must stop taking any targeted medication for at least 2 weeks before participating in the study.
Select...
You require surgery to remove the tumor.
Select...
You haven't taken bevacizumab for at least 4 weeks.
Select...
You are expected to live for at least three more months.
Select...
The neurosurgeon believes that after the tumor is removed, there will be no physical connection between the space where the tumor was and the fluid-filled spaces in the brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Secondary outcome measures
Changes in HSPG and survivin expression
Body Weight Changes
Changes in tumor growth
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (NSC-CRAd-S-pk7)Experimental Treatment2 Interventions
Patients undergo standard of care surgical resection. Patients then receive NSC-CRAd-S-pk7 intracerebrally over 10 minutes QW for up to 4 doses in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Resection
2021
Completed Phase 2
~410

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
561 Previous Clinical Trials
1,918,216 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,927,311 Total Patients Enrolled
Jana L PortnowPrincipal InvestigatorCity of Hope Medical Center
4 Previous Clinical Trials
102 Total Patients Enrolled

Media Library

NSC-CRAd-S-pk7 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05139056 — Phase 1
Anaplastic Astrocytoma Research Study Groups: Treatment (NSC-CRAd-S-pk7)
Anaplastic Astrocytoma Clinical Trial 2023: NSC-CRAd-S-pk7 Highlights & Side Effects. Trial Name: NCT05139056 — Phase 1
NSC-CRAd-S-pk7 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05139056 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~21 spots leftby Aug 2025